The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Cabazitaxel MSN 60 mg concentrate and solvent for solution for infusion

MSN Labs Europe LimitedPA23250/002/001

Main Information

Trade NameCabazitaxel MSN 60 mg concentrate and solvent for solution for infusion
Active SubstancesCabazitaxel
Dosage FormConcentrate and solvent for solution for infusion
Licence HolderMSN Labs Europe Limited
Licence NumberPA23250/002/001

Group Information

ATC CodeL01CD04 cabazitaxel


License statusAuthorised
Licence Issued28/01/2022
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceCondition of licence: Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Marketing StatusUnknown


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back